 | | Vol. 14.25 – 15 July, 2022 |
| |
|
|
| Investigators found that dietary methionine restriction reduced tumor growth and enhanced antitumour immunity by increasing the number and cytotoxicity of tumour-infiltrating CD8+ T cells in different mouse models.
[Gut] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Atypical findings were presented that are observed in a knockin mouse model carrying a lysine to arginine substitution at residue 74 of Krüppel-like factor 1 that displayed significant improvement in geriatric disorders and lifespan extension.
[Advanced Science] |
|
|
|
| The authors tested whether host immune responses against graft-resident commensal microbes, including Staphylococcus epidermidis, could damage colonized grafts independently from the alloresponse.
[Journal of Clinical Investigation] |
|
|
|
| Researtchers reported a cell-intrinsic feedback mechanism that controled the pathogenicity of Th17 cells.
[Journal of Experimental Medicine] |
|
|
|
| Investigators demonstrated that glioma cells could sustain growth independent of immune system constraint by reducing Notch signaling.
[Developmental Cell] |
|
|
|
| Mechanistically, interleukin-1β derived from IFN-γ-polarized tumor macrophages triggered PIM2 expression in cancer cells via the p38 MAPK/Erk and NF-κB signaling pathways.
[Cancer Research] |
|
|
|
| Researchers found that Mycobacterium tuberculosis protein PPE2 and a synthetic derivative peptide could suppress the mast cell population and inhibit several vasoactive and fibrogenic mediators.
[EMBO Molecular Medicine] |
|
|
|
| PD-1/VEGFR2 dual blockade did not exert tumor-inhibitory effects without pre-treatment with the epidermal growth factor receptor-TKI, suggesting that treatment schedule is crucial for efficacy of the dual blockade therapy.
[Cancer Immunology Research] |
|
|
|
| The authors employed single-cell RNA sequencing to create a cell atlas of the early-adolescent pig thymus.
[Cell Reports] |
|
|
|
| Scientists showed that THEMIS promoted the development of optimal type 1 immune responses to foreign antigens but stimulated signals that favored encephalitogenic responses to self-neuroantigens.
[Science Signaling] |
|
 |
|
|
|
| Investigators review the role and mechanism of CD38+ CD4+ T cells / CD38+ CD8+ T cells in cellular immunity and the effects of the CD38-NAD+ axis on T cell activity.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| Repertoire Immune Medicines announced its research collaboration with Memorial Sloan Kettering Cancer Center to identify the immune system’s response at various stages of human papillomavirus-positivecancer, including initial oncogenesis and after successful treatment.
[Repertoire Immune Medicines] |
|
|
|
|
| November 1 – 6, 2022
Virtual |
|
|
|
|
|
| | University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | University Hospital of Muenster – Münster, Germany |
|
|
|
| | Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| | The Chinese University of Hong Kong – Hong Kong, China |
|
|
|
| | Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
